JPH11513021A5 - - Google Patents

Info

Publication number
JPH11513021A5
JPH11513021A5 JP1997507373A JP50737397A JPH11513021A5 JP H11513021 A5 JPH11513021 A5 JP H11513021A5 JP 1997507373 A JP1997507373 A JP 1997507373A JP 50737397 A JP50737397 A JP 50737397A JP H11513021 A5 JPH11513021 A5 JP H11513021A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1997507373A
Other languages
English (en)
Japanese (ja)
Other versions
JPH11513021A (ja
Filing date
Publication date
Priority claimed from GBGB9515811.9A external-priority patent/GB9515811D0/en
Priority claimed from GBGB9526377.8A external-priority patent/GB9526377D0/en
Priority claimed from GBGB9605868.0A external-priority patent/GB9605868D0/en
Priority claimed from GBGB9611898.9A external-priority patent/GB9611898D0/en
Application filed filed Critical
Priority claimed from PCT/GB1996/001862 external-priority patent/WO1997004779A1/en
Publication of JPH11513021A publication Critical patent/JPH11513021A/ja
Publication of JPH11513021A5 publication Critical patent/JPH11513021A5/ja
Ceased legal-status Critical Current

Links

JP9507373A 1995-08-02 1996-08-02 キノロン類およびその医療上の使用 Ceased JPH11513021A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GBGB9515811.9A GB9515811D0 (en) 1995-08-02 1995-08-02 Novel compounds
GB9515811.9 1995-08-02
GBGB9526377.8A GB9526377D0 (en) 1995-12-22 1995-12-22 Novel compounds
GB9526377.8 1995-12-22
GBGB9605868.0A GB9605868D0 (en) 1996-03-20 1996-03-20 Novel compounds
GB9605868.0 1996-03-20
GB9611898.9 1996-06-07
GBGB9611898.9A GB9611898D0 (en) 1996-06-07 1996-06-07 Quinolones and their therapeutic use
PCT/GB1996/001862 WO1997004779A1 (en) 1995-08-02 1996-08-02 Quinolones and their therapeutic use

Publications (2)

Publication Number Publication Date
JPH11513021A JPH11513021A (ja) 1999-11-09
JPH11513021A5 true JPH11513021A5 (2) 2004-09-09

Family

ID=27451319

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9507373A Ceased JPH11513021A (ja) 1995-08-02 1996-08-02 キノロン類およびその医療上の使用

Country Status (12)

Country Link
US (1) US5891878A (2)
EP (1) EP0841929B1 (2)
JP (1) JPH11513021A (2)
AT (1) ATE239477T1 (2)
AU (1) AU696390B2 (2)
CA (1) CA2225552A1 (2)
DE (1) DE69628019T2 (2)
DK (1) DK0841929T3 (2)
ES (1) ES2193252T3 (2)
MX (1) MX9800922A (2)
PT (1) PT841929E (2)
WO (1) WO1997004779A1 (2)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
IT1296985B1 (it) * 1997-12-19 1999-08-03 Zambon Spa Derivati benzazinici inibitori della fosfodiesterasi 4
EP1042295B1 (en) * 1997-12-22 2005-09-07 Pharmacia & Upjohn Company LLC 4-hydroxyquinoline-3-carboxamides and hydrazides as antiviral agents
IT1302677B1 (it) 1998-10-15 2000-09-29 Zambon Spa Derivati benzazinici inibitori della fosfodiesterasi 4
US6248739B1 (en) * 1999-01-08 2001-06-19 Pharmacia & Upjohn Company Quinolinecarboxamides as antiviral agents
US6248736B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents
PL200923B1 (pl) 1999-08-21 2009-02-27 Nycomed Gmbh Lek zawierający inhibitor PDE w połączeniu z agonistą receptoraß₂ -adrenergicznego oraz zastosowanie połączenia roflumilastu i salmeterolu
US6436971B2 (en) * 2000-02-09 2002-08-20 Smithkline Beecham Corporation Use of PDE 4-specific inhibitors to reduce the severity of a bacterial infection after a respiratory viral infection
CA2399741A1 (en) 2000-03-21 2001-11-01 Scott D. Larsen 4-hydroxycinnoline-3-carboxyamides as antiviral agents
NZ521523A (en) 2000-03-21 2004-05-28 Upjohn Co 4-hydroxy-1,8-naphthyridine-3-carboxamides as antiviral agents
KR20020093849A (ko) 2000-03-21 2002-12-16 파마시아 앤드 업존 캄파니 항바이러스제로서의4-옥소-1,4-디히드로[1,8]나프티리딘-3-카르복스아미드
KR20020081479A (ko) 2000-03-21 2002-10-26 파마시아 앤드 업존 캄파니 항바이러스제인4-옥소-1,4-디히드로-3-신놀린카르복스아미드
PE20011349A1 (es) * 2000-06-16 2002-01-19 Upjohn Co 1-aril-4-oxo-1,4-dihidro-3-quinolincarboxamidas como agentes antivirales
US6559145B2 (en) * 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US6730682B2 (en) * 2000-07-12 2004-05-04 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US6562822B2 (en) 2000-07-12 2003-05-13 Pharmacia & Upjohn Company Heterocyle carboxamides as antiviral agents
TWI243164B (en) 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
PE20020856A1 (es) * 2001-02-13 2002-11-11 Aventis Pharma Gmbh 1,2,3,4-tetrahidronaftil aminas aciladas
WO2002070487A1 (en) 2001-03-01 2002-09-12 Pharmacia & Upjohn Company Substituted quinolinecarboxamides as antiviral agents
BR0212829A (pt) * 2001-09-26 2004-08-03 Bayer Pharmaceuticals Corp Derivados de 1,8-naftiridina e seu uso para tratar diabetes e distúrbios relacionados
PT1490392E (pt) * 2002-04-01 2007-04-30 Univ Florida Quinóis esteroidais como pró-fármacos de antioxidantes
US20070213310A1 (en) * 2002-04-01 2007-09-13 Laszlo Prokai Prodrugs for Use as Ophthalmic Agents
US7186707B2 (en) * 2002-04-01 2007-03-06 University Of Florida Prodrugs for use as ophthalmic agents
US7300926B2 (en) * 2002-04-01 2007-11-27 University Of Florida Research Foundation, Inc. Steroidal quinols and their use for estrogen replacement therapy
WO2004069248A1 (en) * 2002-12-09 2004-08-19 University Of Florida Prodrugs for use a ophthalmic agents
JP2006522151A (ja) 2003-04-01 2006-09-28 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 不妊症におけるホスホジエステラーゼ阻害剤
WO2005009971A1 (ja) 2003-07-24 2005-02-03 Astellas Pharma Inc. キノロン誘導体又はその塩
US7470706B2 (en) * 2004-01-31 2008-12-30 Sanofi-Aventis Deutschland Gmbh Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
DE102004004971B3 (de) * 2004-01-31 2005-09-15 Aventis Pharma Deutschland Gmbh Cycloalkyl substituierte 7-Amino-4-chinolon-3-carbonsäure-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arnzeimittel
JP4775259B2 (ja) 2004-03-31 2011-09-21 味の素株式会社 アニリン誘導体
EP2502912A3 (en) * 2004-06-24 2013-11-06 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US8354427B2 (en) * 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
RU2525115C2 (ru) * 2004-06-24 2014-08-10 Вертекс Фармасьютикалз Инкорпорейтед Способ модуляции транспортеров атф-связывающей кассеты
CA2881078C (en) * 2004-06-24 2018-10-02 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
DE102004035203A1 (de) * 2004-07-21 2006-02-16 Bayer Healthcare Ag Substituierte Chinolone
DE102005030524A1 (de) 2005-06-30 2007-01-18 Aicuris Gmbh & Co. Kg Substituierte Chinolone II
WO2007075901A2 (en) * 2005-12-24 2007-07-05 Vertex Pharmaceuticals Incorporated Quinolin- 4 - one derivatives as modulators of abc transporters
AU2006331565A1 (en) * 2005-12-27 2007-07-05 Vertex Pharmaceuticals Incorporated Compounds useful in CFTR assays and methods therewith
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
DE102006005861A1 (de) 2006-02-09 2007-08-23 Aicuris Gmbh & Co. Kg Substituierte Chinolone III
AU2007225088B2 (en) * 2006-03-13 2012-09-13 Kyorin Pharmaceutical Co., Ltd Aminoquinolones as GSK-3 inhibitors
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
MX2011004375A (es) 2008-10-23 2013-03-07 Vertex Pharma Moduladores del regulador de conductancia transmembrana de fibrosis quistica.
SI3330255T1 (sl) 2009-03-20 2021-03-31 Vertex Pharmaceuticals Incorporated Postopek izdelave regulatorja transmembranske prevodnosti pri cistični fibrozi
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
EP2819670B1 (en) 2012-02-27 2026-05-20 Vertex Pharmaceuticals Incorporated Pharmaceutical Composition and Their Administration
GB201409044D0 (en) 2014-05-21 2014-07-02 Ucl Business Plc New compounds
CA2963945C (en) 2014-10-07 2023-01-10 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
CN107998131B (zh) * 2017-12-27 2019-09-24 湖北工业大学 芳香酯类化合物用于制备抗adv-7病毒药物
CN111646941A (zh) * 2020-07-17 2020-09-11 天津科技大学 一种磺酰胺类衍生物及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3524558A (en) * 1967-03-30 1970-08-18 American Mach & Foundry Cargo loading means and method
US3524858A (en) * 1967-05-18 1970-08-18 Warner Lambert Pharmaceutical 1,4 - dihydro-1-substituted alkyl-6,7-methylenedioxy - 4 - oxoquinoline-3-carboxylic acid
FR2564832B1 (fr) * 1984-05-23 1987-05-15 Panmedica Sa Nouveaux n-acyl derives d'amino-acides et leurs esters, leur procede de preparation et medicaments les contenant
US4786644A (en) * 1987-11-27 1988-11-22 Hoechst-Roussel Pharmaceuticals Inc. 1-aryl-3-quinolinecarboxamide
JPH02124871A (ja) * 1988-07-27 1990-05-14 Dainippon Pharmaceut Co Ltd １位が置換された複素環式カルボン酸アミド誘導体

Similar Documents

Publication Publication Date Title
JP2000500440A5 (2)
JP2000500228A5 (2)
JP2000500445A5 (2)
JP2000500327A5 (2)
JP2000500145A5 (2)
JP2000500155A5 (2)
JP2000503050A5 (2)
JP2000500361A5 (2)
JP2000500115A5 (2)
JPH11511346A5 (2)
JP2000500322A5 (2)
JPH11510156A5 (2)
JP2000500258A5 (2)
JP2000500342A5 (2)
JP2000500192A5 (2)
JP2000500112A5 (2)
JP2000500226A5 (2)
JP2000500166A5 (2)
JP2000500051A5 (2)
JP2000500397A5 (2)
JP2000500407A5 (2)
JP2000500019A5 (2)
JPH11510334A5 (2)
JP2001525662A5 (2)
JP2000500346A5 (2)